Edward Thomason, CFA, is a seasoned equity research analyst specializing in the life sciences and healthcare sectors. They began their career at Informa as a pharmaceutical company analyst from 2016 to 2018, followed by a role at Singer Capital Markets from 2018 to 2021, where they led research coverage of AIM-listed companies. Edward continued their expertise at Liberum from 2021 to 2023 as part of the equity healthcare research team. Currently, they serve as the Senior Manager for Life Science M&A lead advisory at Deloitte, following a stint as Vice President of Equity Research at Van Lanschot Kempen. Edward holds a first-class degree in Biomedical Sciences with honors in pharmacology from The University of Edinburgh.
This person is not in the org chart
This person is not in any teams
This person is not in any offices